Dignitana strengthens operating capital through a loan from Adma Förvaltnings AB
The loan will provide operating capital needed to support the Company’s aggressive growth strategy into 2021 focused on the United States, Europe, and Asia.
Adma is the largest shareholder in the Company, holding 26 percent of Dignitana shares. The loan term is 5 months with an option to extend to end of Q1 2021 and is based at STIBOR +700 basis points.
This is information that Dignitana AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 08:10 CET on 30 July 2020.
For More Information Contact
Melissa Bourestom, VP Corporate Communications firstname.lastname@example.org +1 469-518-5031
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Learn more at www.dignitana.se and www.dignicap.com. Eric Penser Bank AB, Certified Adviser, Box 7405,103 91 Stockholm Phone: +46 8-463 83 00 email@example.com www.penser.se
Changes in AroCell's management
“I am very pleased that Gunnar is taking on this position. His experience and knowledge in oncology and urology are very valuable for AroCell and Gunnar has previously made significant contributions in his role as a board member and in specific consulting assignments ", says Michael Brobjer, CEO...
Förändring i AroCells ledning
”Jag är mycket glad att Gunnar knyts närmare företaget. Hans erfarenheter och kunskaper inom onkologi och urologi är mycket värdefulla för AroCell och Gunnar har tidigare haft ett betydande bidrag i sin roll som styrelsemedlem och inom specifika konsultuppdrag”, säger Michael Brobjer, VD på AroCell....
Diabetologia publicerar resultat som belyser effekten av diabetesvaccinet Diamyd[®] i genetiskt definierade undergrupper av typ 1-diabetes
Diabetologia (tidskriften för the European Association for the Study of Diabetes [EASD]) har publicerat resultat från en metastudie som visar en mycket signifikant och kliniskt relevant effekt av Diamyd Medicals ledande läkemedelskandidat Diamyd® (GAD-alum) i att bevara den egna insulinproduktion i...
Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd[®] in genetically defined subgroups of type 1 diabetes
Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) has published results from a meta study that demonstrates a highly significant and clinically relevant effect of Diamyd Medical’s lead drug candidate Diamyd® (GAD-alum) on preserving endogenous insulin production...